ADHD Drug Prescription Trends Are Determined By Side Effect Profile, Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Study in Journal of Managed Care Pharmacy finds more patients are prescribed atomoxetine when they have psychiatric conditions that could be exaggerated by stimulants.
You may also be interested in...
ADHD Black Box Warning On Psychiatric/Cardiac Events Is Unnecessary, Pediatric Committee Says
FDA’s Pediatric Advisory Committee recommends adding regular warnings on possible psychosis, aggression, and cardiovascular risks to all attention deficit/hyperactivity disorder drugs.
FDA Issues Strattera Public Health Advisory On Suicidal Thinking
Advisory alerts physicians to the risk of suicidal thinking in children and adolescents related to use of Eli Lilly's ADHD therapy atomoxetine.
GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates
The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.